SCHEMBL14809489

SCHEMBL14809489

CC(=O)NC(C)(C)c1ccc(-c2ccc(Br)cc2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.41
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ACACB O00763 4/20 0.39
THRB P10828 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
PDE2A O00408 1/20 0.37
KIF11 P52732 1/20 0.36
PTPN1 P18031 2/20 0.36
PTPN2 P17706 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PTPN6 P29350 1/20 0.35
PTPN11 Q06124 1/20 0.35
SLC22A12 Q96S37 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14809386 0.84 NPC1 (0.40) TP53NPC1NFKB1MAPK1RAB9A
SCHEMBL981300 0.84 RXFP1 (0.53) NPC1MAPK1RAB9ASMN1; SMN2ACACB
SCHEMBL165889 0.80 ACACB (0.48) NPC1RAB9ASMN1; SMN2ACACBPDE2A
SCHEMBL16260372 0.77 NPC1 (0.49) TP53NPC1NFKB1MAPK1RAB9A
SCHEMBL14809848 0.74 NPC1 (0.46) TP53NPC1NFKB1MAPK1RAB9A
SCHEMBL14808848 0.73 ACACB (0.44) TP53NPC1NFKB1RAB9ANFKB2
SCHEMBL608849 0.73 ACACB (0.44) RAB9ASMN1; SMN2ACACBALDH1A1
SCHEMBL21016975 0.72 HCAR3 (0.47) TP53L3MBTL1ACACBALDH1A1
SCHEMBL27254652 0.71 ACACB (0.54) NPC1RAB9ASMN1; SMN2ACACBPDE2A
SCHEMBL21016981 0.71 ACACB (0.42) TP53L3MBTL1ACACBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2758059-B1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME (US) 2018-10-24 EP disclosed
US-9079930-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-07-14 US disclosed
US-9079930-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-07-14 US disclosed
US-20140349972-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP (US) 2014-11-27 US disclosed
US-20140349972-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP (US) 2014-11-27 US disclosed
EP-2758059-A1 SUBSTITUTED PYRIMIDINES Merck Sharp & Dohme Corp. (US) 2014-07-30 EP disclosed
WO-2013040790-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
WO-2013043624-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
WO-2013043624-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349972-A1 SUBSTITUTED PYRIMIDINES HIF1AN, HIF1A, EGLN3 TP53 692/4885NPC1 3276/4885NFKB1 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.